Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.

Cancer GIST Gamma secretase Sarcoma Targeted therapy

Journal

Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030

Informations de publication

Date de publication:
25 Dec 2023
Historique:
received: 07 11 2023
revised: 18 12 2023
accepted: 21 12 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 30 12 2023
Statut: aheadofprint

Résumé

Desmoid tumors (DT) are rare, slow-growing, locally invasive soft tissue tumors that often pose significant therapeutic challenges. Traditional management strategies including active surveillance, surgery, radiotherapy, and systemic therapy which are associated with varying recurrence rates and high morbidity. Given the challenging nature of DT and the modest outcomes associated with current treatment strategies, there has been a growing interest in the field of γ-secretase inhibitors as a result of its action on the Wnt/β-catenin signaling pathway. In this review article, we will shed the light on the pathogenesis and molecular biology of DT, discuss its symptoms and diagnosis, and provide a comprehensive review of the traditional therapeutic approaches. We will also delve into the mechanisms of action of γ-secretase inhibitors, its efficacy, and the existing preclinical and clinical data available to date on the use of these agents, as well as the potential challenges and future prospects in the treatment landscape of these tumors.

Identifiants

pubmed: 38159438
pii: S0305-7372(23)00168-8
doi: 10.1016/j.ctrv.2023.102675
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102675

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Rebecca Ibrahim (R)

Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.

Tarek Assi (T)

Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France; Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Tarek.assi@gustaveroussy.fr.

Rita Khoury (R)

Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.

Carine Ngo (C)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Matthieu Faron (M)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Benjamin Verret (B)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Antonin Lévy (A)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Charles Honoré (C)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Clémence Hénon (C)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Cécile Le Péchoux (C)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Ratislav Bahleda (R)

Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Axel Le Cesne (A)

Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France; Sarcoma Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Classifications MeSH